Aminopyridazinone compounds as protein kinase inhibitors
US9951077B2 · kind B2 · utility
5Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2014 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Oct 20, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.